Myocardial infarction (heart attack; abbreviated as \"MI\") remains a major clinical problem and the leading causes of mortality in the world. In the United States alone, approximately 1 million people suffer MI each year. In the UK, the annual incidence of MI (using 2006 CHD mortality data) was estimated to be about 146 000 of all aged individuals (men: ∼87 000 and women: ∼59 000), and the estimated prevalence in those aged \>35 years is more than 1.4 million (men: ∼970 000 and women: ∼439 000).\[[@ref1]\] MI can be defined by pathology as myocardial cell death due to prolonged ischemia.\[[@ref2]\] The most common cause of MI is coronary atherosclerotic plaque rupture or erosion, resulting in the exposure of thrombogenic contents to the blood. This leads to thrombus formation and consequently MI. Several risk factors are associated with MI as listed below.

The risk factors include

non-modifiable risk factors: age, gender, low-birth weight, race/ethnicity, genetic factors;well-documented and modifiable risk factors: Hypertension, exposure to cigarette smoke, diabetes, atrial fibrillation and certain other cardiac conditions, dyslipidemia, carotid artery stenosis, sickle cell disease, postmenopausal hormone therapy, poor diet, less physical activity, obesity, and body fat distribution; andless well-documented or potentially modifiable risk factors: Metabolic syndrome, alcohol abuse, drug abuse, oral contraceptive use, sleep-disordered breathing, migraine headache, hyperhomocysteinemia, elevated lipoprotein(a), elevated lipoprotein-associated phospholipase, hypercoagulability, inflammation, infection.\[[@ref3]\]

Cardiac troponins are more specific markers of myocardial necrosis. The measurement of cardiac troponins is the new gold standard diagnostic indicator of myocardial injury. These molecules are valuable and sensitive cardiac biochemical markers for the heart damage compared with total creatine kinase or its isoform, creatine kinase-MB.\[[@ref4]\] \"The Universal Definition of MI requires detection of increasing or decreasing cardiac biomarkers (preferably cardiac troponin) with ≥1 value \>99th percentile, together with clinical symptoms, new ischemic electrocardiographic changes, or typical imaging findings indicative of myocardial necrosis as diagnostic criteria for acute myocardial infarction\".\[[@ref5]\]

The treatment of MI involves reperfusion therapy to reduce early mortality rates.\[[@ref6]\] The drug therapy includes treatment with the combination of the following (Grade A): angiotensin-converting enzyme inhibitor, aspirin (an antiplatelet drug), beta-blocker, and statin.\[[@ref7]\] Existing therapies lower the early mortality rates, prevent additional damage to the heart muscle, and reduce the risk of further heart attacks. However, there is need for a treatment to improve the clinical conditions by replacing the damaged heart cells. Thus, the cardiac tissue regeneration with the application of stem cells may be an effective therapeutic option.

Stem cells (both adult and embryonic stem cells \[ESCs\]) have the ability to self-replicate and transform into an array of specialized cells. Stem cells (unspecialized) are becoming the most important tool in \"regenerative medicine.\"\[[@ref8]\] These cells have the potential to differentiate into cardiomyocytes. It would, therefore, be useful to find out if the differentiated cells can restore and improve cardiac function with efficacy and a good safety profile.

In the present review, we summarize the recent progress in this field of science and focus on the potential clinical applications of stem cells in the cardiac repair.

Types of Stem Cells {#sec1-1}
===================

Both embryonic and adult stem cells are sources of undifferentiated cells, with the ability to repair and regenerate tissue. Some of the stem cell types that can be used to improve infarcted heart are as follows: embryonic, cardiac, cardiomyocyte progenitor cells, hematopoietic cells, bone marrow mesenchymal stem cells, skeletal myoblast, fetal and umbilical cord blood cells.\[[@ref9]--[@ref13]\] Several routes can be used to deliver such cells to the human myocardium or to the coronary circulation. These routes include intravenous infusion, direct injection into the ventricular wall, or transepicardial/transendocardial infusions. However, questions relating to dose, timing, and route of administration need to be addressed.

Embryonic stem cells {#sec2-1}
--------------------

ESCs hold promise for myocardial cellular therapy, but the clinical use of these cells raises ethical issues and political controversies.\[[@ref14]\] The ethical problems specific to ESC research, however, can be avoided by reprogramming somatic cells to produce induced pluripotent stem cells. Takahashi and Yamanaka\[[@ref15]\] demonstrated the induction of pluripotent stem cells from mouse embryonic or adult fibroblasts by introducing four factors (Oct3/4, Sox2, c-Myc, and Klf4). The induced pluripotent stem cells showed the morphology and growth properties of ESC and expressed ESC marker genes. More recently, Zhang *et al*.\[[@ref16]\] have shown that human-induced pluripotent stem cells can differentiate into functional cardiomyocytes and these cells may be suitable for therapeutic application.

Kehat *et al*.\[[@ref17]\] have succeeded in growing the heart cells from human ESCs. The results showed that human ESCs have the ability to differentiate into myocytes with the structural and functional properties of cardiomyocytes. The preclinical studies have shown that ESC transplant results in improvement in cardiac structure and function.\[[@ref18]--[@ref20]\] Caspi *et al*.\[[@ref21]\] evaluated the ability of human ESCs and their cardiomyocyte derivatives to engraft and improve myocardial performance in the rat chronic infarction model. The results of this study showed the formation of stable cardiomyocyte grafts, attenuation of the remodeling process, and functional benefit, highlighting their potential for myocardial cell therapy strategies.

Adult stem cells {#sec2-2}
----------------

Currently, adult stem cells are the only stem cell types that can be used for transplant to treat diseases like MI. These unspecialized cells are found in within a tissue or organ and have the ability to develop into specialized cells. The purpose of these cells is to primarily maintain and repair the tissue in which they are found. The adult human heart contains small populations of indigenous committed cardiac stem cells or multipotent cardiac progenitor cells. These stem cells are intrinsically programmed to generate cardiac tissue.\[[@ref22]\] The markers used to identify cardiac stem cells and their biologic functions in human are SSEA-1, Oct-3/4, Isl-1, c-Kit (CD117, SCFR), Sca-1 (Ly 6), MDR-1 (Abcb1, Pgp), Abcg2 (MXR1, BCRP), CD133 (prominin), CD90 (Thy-1), CD105 (endoglin), CD34, CD31(PECAM-1), and CD45 (LCA).\[[@ref23]\] To date, at least five apparently different cardiac stem and/or progenitor cell types have been described.

In addition, the adult bone marrow stem cells consist of hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. Orlic *et al*.\[[@ref24]\] first suggested that bone marrow cells have the ability to regenerate infarcted myocardium. Mangi *et al*.\[[@ref25]\] genetically engineered rat mesenchymal stem cells using ex vivo retroviral transduction and these stem cells repaired infarcted myocardium. Recent study showed that granulocyte colony-stimulating factor promoted bone marrow cells to migrate into the infarcted heart and differentiate into cardiomyocytes; however, proportional contribution of cells from bone marrow was small when compared with non-bone marrow in the infarction model.\[[@ref26]\] Zhang *et al*.\[[@ref27]\] identified a single non-hematopoietic mesenchymal stem cell subpopulation isolated from human bone marrow, clonally purified, and compared the effects with unpurified mesenchymal stem cell, mononuclear cells, or peripheral blood mononuclear cells on myocardial repair after induction of MI in rats. They observed that transplantation with single clonally purified mesenchymal stem cells was more beneficial to the cardiac repair when compared with other stem cells. Recent in vivo studies indicate that engrafted bone marrow cells survive and grow within the spared myocardium after infarction by forming junctional complexes with resident myocytes. These cells generate de novo myocardium composed of integrated cardiomyocytes and coronary vessels.\[[@ref28]\] Previously, we tried to find out if bone marrow-derived stem cells from patients can differentiate into cardiomyocyte precursors when cocultured with atrial tissue condition medium, and we observed that these cells resembled smooth muscles probably cardiomyocytes.\[[@ref29]\] Further studies need to be conducted to confirm the results. More recently, a randomized, double-blind, placebo-controlled, dose-escalation study (reperfused MI patients \[*n* = 53\])\[[@ref30]\] showed that intravenous allogeneic human mesenchymal stem cells are safe in patients after MI.

Studies have also shown that adipose tissue-derived cells have the ability to give rise to functional cardiomyocyte-like cells.\[[@ref31]\] Adipose tissue contains a population of adult multipotent mesenchymal stem cells and endothelial progenitor cells with extensive proliferative capacity. These cells have the potential to differentiate into several lineages including cardiomyocytes, suggesting their potential as cell source for repairing the damaged tissues. More recently, Bai *et al*.\[[@ref32]\] showed that both freshly isolated human adipose tissue-derived cells and cultured human adipose tissue-derived stem cells engrafted into infarcted myocardium survived and improved myocardial function. The results suggest that both cells are promising alternative source for myocardial repair post-MI. To explore the clinical application of human stem cells, Kim *et al*.\[[@ref33]\] transplanted human unrestricted somatic stem cells into porcine hearts post-MI. Four weeks after transplantation, the engrafted cells were detected in the infarct region, resulting in improved regional and global function of the porcine heart, suggesting positive potential for their implantation for cellular cardiomyoplasty.

Umbilical cord blood is a source of human hematopoietic precursor cells. These cells have a potential for cell-based therapy to treat acute MI by contributing to the repair processes post-MI, thus providing a useful therapeutic option.\[[@ref34]\] Wu *et al*.\[[@ref35]\] investigated the therapeutic potential of human umbilical cord-derived stem cells in a rat MI model. They showed that transplanted cells provide benefit in cardiac function recovery after acute MI. More recently, Schlechta *et al*.\[[@ref36]\] have shown that umbilical cord blood-derived hematopoietic precursor cells can be reproducibly expanded ex vivo and retain their potential to improve cardiac function post-MI.

Comparison of Stem Cells {#sec1-2}
========================

Both adult and ESCs can be used to improve an infarcted heart. The best cell type as a source for transplantation into the ischemic heart remains a controversy because of lack of well-defined cell markers. Studies need to address the source and the best types of stem cells for clinical applications \[[Table 1](#T1){ref-type="table"}\].
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Stem Cell-based Therapy {#sec1-3}
=======================

Currently, various therapeutic options are available to heal the damaged heart. Gene therapy is an interesting option, but the use of viral vectors for gene delivery is a concern due to safety issues. Another more promising addition to the existing option is the cell replacement therapy. Both *in vitro* and *in vivo* studies performed in animal models have demonstrated that the transplanted cells undergo differentiation in an attempt to repair damaged myocardium.\[[@ref37][@ref38]\] Previous studies in the animal models have suggested that ESC transplantation post-MI is beneficial. In rats, ESCs differentiated into cardiomyocytes and improved cardiac function.\[[@ref39]\] Singla *et al*.\[[@ref40]\] have concluded that transplanted mouse ESCs have the ability to regenerate infarcted myocardium and improve cardiac structure and function. Kolossov *et al*.\[[@ref41]\] have examined the fate and functional impact of bone marrow cells and ESC-derived cardiomyocytes after transplantation into the infarcted mouse heart. The results have shown that ESC-based therapy is a promising approach for the treatment of impaired myocardial function; this therapy also provides better results when compared with the bone marrow-derived cells. Mangi *et al*.\[[@ref42]\] have genetically engineered rat mesenchymal stem cells that have the ability to repair infarcted myocardium to nearly normal cardiac performance. A new therapeutic strategy for cardiac tissue regeneration was discovered when Miyahara *et al*.\[[@ref43]\] cultured adipose tissue-derived mesenchymal stem cells and transplanted the monolayered cells onto the scarred myocardium that improved cardiac function in rats.

The results from the clinical studies have demonstrated a good safety profile with improved cardiac function, and favorable effects in patients with MI.\[[@ref44]--[@ref49]\] The randomized controlled clinical trial (60 patients; 6-month follow-up)\[[@ref45]\] has shown that intracoronary transfer of autologous bone-marrow cells promoted improvement of left-ventricular systolic function in MI patients. The trial (59 patients with acute MI) has demonstrated that intracoronary infusion of progenitor cells (circulating progenitor or bone marrow-derived progenitor cells) is safe and feasible in patients after acute MI successfully revascularized by stent implantation.\[[@ref46]\] In a prospective, nonrandomized, open-label study with five heart transplant candidates with severe ischemic heart failure, the autologous bone-marrow mononuclear cell injections were performed safely and resulted in improved exercise capacity (6-month follow-up evaluation).\[[@ref47]\] In the cell-randomized clinical trial (27 patients), granulocyte colony-stimulating factor therapy with intracoronary infusion of peripheral blood stem cells have shown improved cardiac function, and promoted angiogenesis in MI patients.\[[@ref48]\] Bartunek *et al*.\[[@ref49]\] in Phase I/II study have shown that intracoronary administration of enriched bone marrow CD133+ cells in patients with acute MI (19/35 patients) although feasible is associated with increased incidence of coronary events.

Autologous cell transplantation uses stem cells to regenerate myocardium. This process involves implantation of bone marrow stem cells into the infarcted area of heart in an effort to restore the viability of the tissue. Stamm *et al*. have injected autologous AC133^+^ bone marrow cells into the infarct area of patients with MI and restored tissue viability.\[[@ref50]\] A clinical trial\[[@ref51]\] in patients with old MI and ischemic coronary artery disease (*n* = 12) has shown that treatment with skeletal myoblast in conjunction with coronary artery bypass is safe and feasible. A randomized controlled trial\[[@ref52]\] (69 patients with acute MI) has shown that transplantation of bone marrow mesenchymal stem cells might improve cardiac function and is safe and feasible with no deaths or malignant arrhythmias. In another clinical trial, Katritsis *et al*.\[[@ref53]\] have shown that intracoronary transplantation of mesenchymal stem cells and endothelial progenitors is feasible, safe, and may also contribute to regional regeneration of myocardial tissue early or late following MI. Klein *et al*.\[[@ref54]\] in a Phase I clinical study have shown that CD133^+^ -enriched stem cell transplantation improved cardiac function in all patients. Li *et al*.\[[@ref55]\] have shown that autologous peripheral blood stem cell transplantation by intracoronary infusion in patients with acute MI is safe. A Phase I/IIa double-blind, randomized, placebo-controlled, dose-escalating trial\[[@ref56]\] of intramyocardial injection of autologous CD34^+^ cells in patients with intractable angina (*n* = 24) provided evidence for feasibility, safety, and bioactivity. Furthermore, a larger Phase IIb study is underway to evaluate this therapy. In the Doppler substudy of the randomized, double-blind, placebo-controlled Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction trial,\[[@ref57]\] microvascular function of the infarct-related artery was restored after intracoronary transplantation of bone marrow progenitor cells in patients with reperfused acute MI. In an open-labeled prospective clinical trial, Choi *et al*.\[[@ref58]\] have shown that intracoronary transplantation of autologous peripheral blood stem cells (mobilized by granulocyte colony-stimulating factor) was safe in patients who underwent percutaneous coronary intervention and improved myocardial function, but could not significantly improve left ventricular function compared with standard reperfusion treatment. Balogh *et al*.\[[@ref59]\] transplanted autologous bone marrow-derived CD34 ^+^ stem cells in patients with MI, and these cells improved left ventricular function and viability after MI. A Phase I clinical study\[[@ref60]\] has shown CD133^+^ -enriched stem cell transplantation into ischemic myocardium without coronary artery bypass grafting that was feasible, safe, and improved cardiac function in all patients. More recently, in a prospective, randomized study (60 patients), Gyöngyösi *et al*.\[[@ref61]\] have compared the safety and feasibility of early and late delivery of bone marrow mononuclear stem cells after MI with combined delivery approach. They have shown that this approach induces a moderate but significant improvement in myocardial infarct size and left ventricular function. Recently, Martin-Rendon *et al*.\[[@ref62]\] have evaluated evidence from randomized control trials on the effectiveness of adult bone marrow-derived stem cells to treat acute MI (13 RCTs; 811 participants). The results of this systematic review have suggested that there is little evidence to assess the clinical effects of this treatment. Mohyeddin-Bonab *et al*. \[[@ref63]\] have investigated the efficacy of autologous bone marrow-derived mesenchymal stem cells in improving the heart function in patients (*n* = 8) with old MI. They have shown that this transplantation is safe, feasible, and that the cells improved the cardiac function without serious adverse effects. Meluzín *et al*.\[[@ref64]\] have shown that the autologous mononuclear bone marrow cell transplantation (60 patients) provided sustained improvement in global left ventricular systolic function in patients with acute MI. More recently, in a Phase I clinical trial, Krause *et al*.\[[@ref65]\] have shown that (12-month follow-up) left ventricular electromechanical mapping and percutaneous intramyocardial cell injection in patients with acute MI was a safe procedure.

Discussion {#sec1-4}
==========

The paradigm that the adult heart is a postmitotic organ was established in the 1970s. Later, this concept was changed because of the growing body of evidence challenging this traditional view. In adults, myocardium can regenerate from the cardiac stem cells that enter the cell cycle, contributing to changes in the myocardial mass.\[[@ref66][@ref67]\] A low level of cardiomyocyte renewal may occur throughout life, which may be in response to cardiac stem cell activity or migration of stem cells from distant tissues. Such repair following MI is grossly inadequate to compensate for the severe loss of functional cardiomyocytes. Existing therapies lower the early mortality rates, prevent additional damage to the heart muscle, and reduce the risk of further heart attacks. However, there is need for a treatment to improve the clinical conditions by replacing the damaged heart cells. Thus, the cardiac tissue regeneration with the application of stem cells may be an effective therapeutic option.

The regeneration of cardiomyocytes (heart muscle cells) to improve postinfarcted heart with the application of stem cells has been broadly studied. Recently, interest has been concentrated on myocardial regeneration with the application of stem cells. Studies have shown that both embryonic and adult stem cells have the ability to repair and regenerate tissue, and in turn, these cell types can be used in the cardiomyocyte regeneration. However, there are major hurdles for the therapeutic use of adult stem cells which include harvesting and expansion of cells *in vitro*, advanced methods to obtain desired cell types, optimization of route of administration of stem cells, and specific induction of heart tissue regeneration.

ESCs hold promise for myocardial cellular therapy, but the clinical uses of these cells raise ethical issues and political controversies. The ethical issues specific to ESC research can be avoided by reprogramming somatic cells to produce induced pluripotent stem cells. *In vitro* human ESCs give rise to cardiomyocytes; however, the regenerative capacity of undifferentiated human ESCs after *in vivo* engraftment needs to be established. The major hurdle for the clinical application of ESCs is the formation of teratoma by undifferentiated cells, as they may not be directed to form new myocardium after transplantation.

Although ESCs have potential to repair the damaged tissue, the use of ESCs carries a threat for neoplastic transformation due to inherent risk for unguided differentiation. The malignant tumorigenic potential of ESCs needs to be defined, and the risk of teratoma formation has to be eliminated before ESC-based therapy is considered. Guided cardiopoiesis uses the definitive engagement of stem cells to generate cardiac tissue avoiding teratomas. Cardiopoietic programming offers a tumor-resistant approach for regeneration. Behfar *et al*.\[[@ref68]\] demonstrated that use of cardiopoietic cells eliminates reliance on host heart signaling for differentiation. These cells delivered into infarcted hearts generated cardiomyocytes integrating with host myocardium for tumor-free repair. Other challenges include the need for preparations of high cardiac purity, improved delivery methods, and overcome immune rejection and graft cell death.

Research has been focused on understanding how stem cells target injured tissue.\[[@ref69]\] A review by Smart and Riley\[[@ref70]\] focuses on existing insights into the trafficking of stem cells in the context of cardiac regenerative therapy. In addition, the mechanisms of action of stem cell transplantation are not fully understood. The transplanted stem cells into injured tissue express paracrine signaling factors (cytokines, chemokines, and growth factors) involved in the process of stem cell-driven repair. Future studies need to address the mechanistic basis for stem cell-mediated paracrine enhancement.

In conclusion, stem cell transplantation appears to be a safe and effective option for treating the postinfarcted heart. To date, there are several preclinical studies that have demonstrated the potential of stem cell-based therapy in the treatment of MI. These clinical studies have demonstrated a good safety profile, improved cardiac function, and favorable effects in patients with MI. The results obtained from animal studies are promising, and the data obtained from the human clinical trials are even more encouraging.
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